Status:
COMPLETED
Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Post-Herpetic Neuralgia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to measure how rapidly pregabalin treatment can relieve pain in patients with post-herpetic neuralgia
Eligibility Criteria
Inclusion
- Diagnosis of PHN with pain present for at least three months after the healing of a Herpes Zoster skin lesion.
- Subjects must have completed the Daily Pain Rating Scale in the electronic diary at least 4 times during screening and have an average daily pain rating score of greater than or equl to 4 during the 7 +/- 3 days prior to randomization (Visit 2).
Exclusion
- History of neurolytic or neurosurgical therapy for PHN.
- Presence of any severe pain associated with conditions other than PHN that may confound the assessment or self-evaluation of the pain due to PHN.
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
255 Patients enrolled
Trial Details
Trial ID
NCT00159666
Start Date
October 1 2004
End Date
June 1 2006
Last Update
January 22 2021
Active Locations (40)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Phoenix, Arizona, United States
2
Pfizer Investigational Site
Little Rock, Arkansas, United States
3
Pfizer Investigational Site
Duarte, California, United States
4
Pfizer Investigational Site
Denver, Colorado, United States